Liver/Biliary Disorders News

Grifols announced that its at-home service to test for genetic risk related to alpha1-antitrypsin deficiency has received clearance from the FDA.

The FDA has updated the label indication for 25 mg tenofovir alafenamide for the treatment of chronic hepatitis B virus with compensated liver disease, expanding the patient population to include children aged 12 years older.

The FDA issued a complete response letter to Gilead indicating it cannot approve the company’s new drug application that seeks approval of bulevirtide for chronic hepatitis D virus infection and compensated liver disease.

CHARLOTTE, N.C. — Local injury, toxin exposure and systemic disease were among the top contributors to development of diabetes mellitus in patients with acute pancreatitis, according to a researcher at the ACG Annual Scientific Meeting.

Recent and ongoing outbreaks associated with person-to-person transmission have marked a shift in hepatitis A virus epidemiology in the United States, according to data published in Morbidity and Mortality Weekly Report.

Patients with hepatorenal syndrome type 1 and advanced acute-on-chronic liver failure had significantly greater incidence of respiratory failure and 90-day mortality when treated with terlipressin vs. placebo, according to research.

Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release.

In this Healio video, Andrew J. Costandi, MD, MMM, details the Enhanced Recovery After Liver Transplantation protocol at Children’s Hospital Los Angeles, which shortened post-transplant ICU stays from 7 to 3 days in pediatric patients.

Patients who received obeticholic acid for primary biliary cholangitis experienced greater transplant-free survival compared with external control patients, according to research published in Gastroenterology.

A patient outcomes simulator found that non-liver-related mortality could surpass liver-related mortality in patients with nonalcoholic fatty liver disease, depending on age and fibrosis stage at diagnosis, noted data in JAMA Network Open.